Radiation pneumonitis

Clinical Pulmonary Medicine

Volumn 17, Issue 5, 2010, Pages 218-222

  Rovirosa, Angeles ^a   Valduvieco, Izaskun ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

radiation pneumonitis

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CHEMOKINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 1; IFOSFAMIDE; INTERFERON; METHOTREXATE; MITOMYCIN; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ABNORMAL RESPIRATORY SOUND; ATELECTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL HYPERPLASIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; ESOPHAGUS CANCER; FEVER; FIBEROPTIC BRONCHOSCOPY; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LUNG CANCER; LUNG FIBROSIS; LUNG INFILTRATE; LUNG VOLUME; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; RADIATION DOSE; RADIATION PNEUMONIA; RADIATION RESPONSE; RELAPSE; REVIEW; THORAX PAIN; THORAX RADIOGRAPHY; WHOLE BODY RADIATION;

EID: 77957805769     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3181efac67     Document Type: Review

References (50)

1. Groover TA, Christie AC, Merrit EA. Observation on the use of the cooper filter in the roentgent treatment of deep-seated malignancies. South Med J. 1922;15:440-444.
2. Mcdonald S, Rubin P, Philips TL, et al. Injury to the lung from cancer therapy. Int JRadiat Oncol Biol Phys. 1995;144:160-169.
3. Carver JR, Shapiro CL, Ng A, et al. American Society ofClinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991-4008.
4. Tsouttsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mecha-nisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys. 2006;66:1281-1293.
5. Constine LS, Milano MT, Friedman D. Late effects ofcancer treatment on normal tissues. In: Perez CA, Brady L, eds. Principles and Practice of Radiation Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:320-363.
6. Rosai J. Acute pulmonary injury and interstitial pneumonia. In: Rosia J, ed. Ackerman's Surgical Pathology. Vol 1. 8th ed. New York, NY: Mosby; 1996:358-359.
7. Gross NJ. Experimental radiation pneumonitis. Part IV: Leakage ofcircula-tory proteins onto the alveolar surface. JLab Clin Med. 1980;95:19-31.
8. Abdollahi A, Li M, Ping G, et al. Inhibition ofplatelet-derived growth factor signaling attenuates pulmonary fibrosis. JExp Med. 2005;201:925-935.
9. Mah K, Van Dyk J, Keane T, et al. Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys. 1987;13:179-188.
10. Movsas B, Scott C, Langer C, et al. Randomizedtrail ofamifostine in locally advanced non-small-cell-lung caner patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005;23:2545-2154.
11. Inoue A, Kunitoh H, Sekine I, et al. Radiation pneumonitis in lung cancer patients: a retrospective study ofrisk factors and the long term prognosis. Int J Radiat Oncol Biol Phys. 2001;49:649-655.
12. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer: a systematic review. Radiother Oncol. 2004;71:127-138.
13. Park HJ, Kim KJ, Park SH, et al. Early CT findings ofTomotherapy induced radiation pneumonitis after treatment lung malignancy. Am J Roentgenol. 2009;193:209-213.
14. Seppenwoolde Y, de Jaeger K, Boersma LJ, et al. regional differences in lung radiosensivity after radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:748-758. (Pubitemid 39311754)
15. Madani I, De Ruyck K, Goeminne H, et al. Predicting risk of radiation-induced lung injury. JThorac Oncol. 2007;2:864-874.
16. Arenas M. Valoración de la calidad de vida en los pacientes con tumores cerebrales, digestivos y de pulmón. In: Rovirosa A, ed. Calidad de Vida en Los Pacientes Tratados Con Radioterapia. Madrid, Spain: Saned; 2006:17-26.
17. Rubin P, Cassarett G. Clinical Radiation Pathology. Philadelphia, PA: WB Saunders; 1968.
18. Libshitz HI. Radiation changes in lung. Semin Roentgenol. 1993;28:303-320.
19. Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglectedphenomenon. Cancer Treat Rev. 2005;31:555-570.
20. Racanti T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol. 2003;67:275-283.
21. Robnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:89-94.
22. Heinzelmann F, Jendrossek V, Lauber K, et al. Irradiation-induced pneumo-nitis mediated by the CD95/CD95-ligand system. JNatl Cancer Inst. 2006; 98:1248-1251.
23. Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention ofradiation-induced lung toxicity in patients with breast and lung cancer: a double blind randomized trial. Int J Radiat Oncol Biol Phys. 2004;58:213-219.
24. Tsujino K, Hirota S, Endo M, et al. Predictive value of des-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradia-tion for lung cancer. Int JRadiat Oncol Biol Phys. 2003;55:110-115.
25. Shcallenkamp JM, Miller RC, Brinkmann DH. Incidence of radiation pneu-monitis after thoracic irradiation: dose-volume correlates. Int JRadiat Oncol Biol Phys. 2007;67:410-416.
26. Wang S, Liao Z, Wei X. Analysis ofclinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimen-sional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006;66:1399-1407.
27. Oh D, Ahn YC, Park HC, et al. Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors. Jpn J Clin Oncol. 2009; 39:151-157.
28. Thirion P, Holmberg O, Collins CD, et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol. 2004;71:163-166.
29. Bradley JD, Hope A, El Naqa I, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institu-tional data. In J Radiat Oncol Biol Phys. 2007;69:985-992.
30. Brown WT, Fayad WF, Fowler JF, et al. Application ofrobotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent. Clin Oncol. 2009;21:623-631.
31. Hart JP, Mc Curdy MR, Ezhil M, et al. Radiation pneumonitis: correlation of toxicity with pulmonary metabolic response. Int J Radiat Oncol Biol Phys. 2008;71:967-971.
32. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin's disease: disease control and long term complications. Int J Radiat Oncol Biol Phys. 1990;18:275-281.
33. Koh ES, Sun A, Tran TH, et al. Clinical dose-volume histograms analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:223-228.
34. Carruther SA, Wallington MM. Total body irradiation and pneumonitis risk: a review of the outcomes. Br JCancer. 2004;90:2080-2084.
35. Beyzadeoglu M, Oysul K, Diricaan B. Effect ofdose-rate and lung dose in total Body irradiation on interstitial pneumonitis after bone marrow trans-plantation. Tohoku JExp Med. 2004;202:255-263.
36. Schneider RA, Schulttze J, Jensen JM, et al. Long-term outcome after static intensity-modulated total body radiotherapy using compensators stratified by pediatric and adult cohorts. Int JRadiat Oncol Biol Phys. 2008;70:194-202.
37. Sampath S, Schultheiss TE, Wong J. Dose response factors related to interstitial pneumonitis after bone marrow transplant. Int JRadiat Oncol Biol Phys. 2005;63:876-884.
38. Harris S. Radiotherapy for early and advanced breast cancer. Int JPract. 2001;55:609-612.
39. Teh AY, Park EJ, Shen L, et al. Three-dimensional volumetric analysis of irradiated lung with adjuvant breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75:1309-1315.
40. Krengli M, Sacco M, Loi G, et al. Pulmonary changes after radiotherapy for conservative treatment ofbreast cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2008;70:1460-1467.
41. Recht A, Ancukiewicz M, Alm M, et al. Lung-dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation using three-dimensional conformal radiotherapy. J Clin Oncol. 2009;27:3887-3893.
42. Utehina O, Popovs S, Purina D, et al. Analysis of cardiac and pulmonary complication probabilities after radiation therapy for patients with early-stage breast cancer. Medicina. 2009;45:276-283.
43. Wang S, Liao Z, Wei X, et al. Association between systemic chemotherapy before chemoradiation and increased risk oftreatment-relates pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Tho-rac Oncol. 2008;3:227-282.
44. Rovirosa A. La Radioterapia del Cáncer de Cabeza y Cuello y sus Efectos Secundarios: Donde Estamos y Hacia Donde Vamos. Madrid, Spain: Saned; 2008.
45. Komaki R, lee JS, Milas L, et al. Effects ofamifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer. Report of a comparative trial. Int J Radiat Oncol Biol Phys. 2004; 58:1369-1377.
46. Koukourakis MI, Romanidis K, Froudarakis M, et al. Concurrent adminis-tration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br JCancer. 2002;87:385-392.
47. Gopal R, Tucker SL, Komaki R, et al. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 2003;56:106-113.
48. Vujaskovic Z, Feng QF, Rabbani ZN, et al. Assessment of the protective effect ofamifostine on radiation-induced pulmonary toxicity. Exp Lung Res. 2002;157:577-590.
49. Antonadou D, Petridis A, Synodinou M, et al. Amifostine reduces radioche-motherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol. 2003;30(suppl 18):2-9. (Pubitemid 38120494)
50. Zhang M, Qian J, Xing X, et al. Inhibition of the tumor necrosis factor-α pathway is radioprotective for lung. Clin Cancer Res. 2008;14:1868-1876.